Pirtobrutinib is a highly selective, non‐covalent (reversible) BTK inhibitor that has garnered significant interest in the treatment of B‐cell malignancies, particularly MCL, where resistance to covalent BTK inhibitors poses a major clinical challenge. Here, BTK is linked to mantle cell lymphoma.